logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Repros Jumps on Positive Drug Trials

By  +Follow September 17, 2013 8:01AM
Share:
Tickers Mentioned:

Shares in Texas pharma Repros Therapeutics, Inc. (RPRX) gapped up over 30 percent in early morning trading before settling into gains of just over 10 percent on heavy volume as the day wore on. The spike, driven by positive topline results from the most recent study on its drug Androxal® reported after close on Monday, pushed Repros stock to a new 52-week high.

Positive results for Androxal

Androxal is being developed for men of reproductive age with low testosterone due to secondary hypogonadism, which is also associated with obesity and could be among the most common causes of low testosterone. Repros reported that Andorxal met both co-primary endpoints in its second pivotal study, with 81 percent of subjects using the drug experiencing normalized testosterone and no 24-hour average testosterone levels outside of normal ranges. Androxal, which is in a class similar to Sanofi’s (SNY) Clomid®, could receive a strong share of the testosterone replacement therapy (TRT) market because it could also help preserve male fertility while being administered orally, making it significantly more convenient than testosterone replacement injections.  

Possible Sale

Brean Capital initiated coverage of Repros in July of this year, calling it a buy and setting a price target of $32. At the time, analyst Jonathan Aschoff said “Its lead compound Androxal is being evaluated in a Phase 3 program for secondary hypogonadism with results in 4Q13 and 2Q14, which in our view would be key investment catalysts, and we project Androxal launch in mid-2015.” Now, Brean is citing these positive results as a reason for optimism, as well as reports that management may have interest in selling the company. Brean estimated the sell-price potentially reaching $40 a share, in the event that the sale goes down.

In addition to Andorxal, Repros currently has female reproductive drug Proellex® in the pipeline, intended for use in uterine fibroids and endometriosis. “The vaginal formulation of Proellex (Proellex-V) will enter Phase 2b in 2H13 for uterine fibroids with an NDA submission expected in 2016. All compounds are protected by U.S. patents," said Aschoff in July.

Results for RPRX
Constantine Greyson
16 Apr 14 19:58:27
$RPRX Repros Completes Enrollment http://t.co/o2coXBkeSp
Tressie Fortenberry
16 Apr 14 19:58:25
$RPRX Repros Completes Enrollment http://t.co/SmdwX1X5yb
Maksim Latimer
16 Apr 14 18:48:43
$RPRX Repros Completes Enrollment http://t.co/GILPZcldX9
Cammie Filman
16 Apr 14 13:28:11
$RPRX Repros Completes Enrollment http://t.co/GyIPjPuh4m
NASDAQ Bridge
16 Apr 14 12:34:05
$RPRX Repros Completes Enrollment for An http://t.co/VhN7Wfl0cE
NASDAQ Keeper
16 Apr 14 12:26:32
$RPRX Repros Completes Enrollment for An http://t.co/y8K7HubtuV
Investment Engineer
16 Apr 14 12:25:02
$RPRX Repros Completes Enrollment for An http://t.co/cIqKhFpYT3
Jaycob Keating
16 Apr 14 11:20:25
$RPRX Repros Completes Enrollment http://t.co/2AIt4QHYT5
Bertie Beyer
16 Apr 14 10:55:57
$RPRX Repros Completes Enrollm http://t.co/EpRoM9Bk7p
Deon Carter
16 Apr 14 10:45:43
$RPRX Repros Completes Enrollment http://t.co/NqqePTscj0
Larry Meath
16 Apr 14 09:56:30
$RPRX Repros Completes Enrollm http://t.co/AypumOXH08
Rob McGavern
16 Apr 14 05:18:19
$RPRX Repros Completes Enrollment http://t.co/TjJSN9l89X
Trystan Jarrett
16 Apr 14 04:49:04
$RPRX Repros Completes Enrollment http://t.co/CQsEO6Z4LK
Lutz Braune
15 Apr 14 22:47:06
$RPRX Repros Completes Enrollment for Androxal Study http://t.co/HJCgNUgFHd
Lutz Braune
15 Apr 14 22:19:37
$RPRX Repros Completes Enrollment for Androxal Study - Analyst Blog http://t.co/XgMzL6Vwty
Cortez Kinlan
15 Apr 14 20:07:26
$RPRX Repros Completes Enrollment http://t.co/yD8D9prkhN
Kamren Dissana
15 Apr 14 19:48:53
$RPRX Repros Completes Enrollment http://t.co/pOUei03CEC
Rudi Shaverek
15 Apr 14 19:30:46
$RPRX Repros Completes Enrollm http://t.co/YOMBlkDcmE
Will Logon
15 Apr 14 19:20:03
$RPRX Repros Completes Enrollment for An http://t.co/MBb0uVTcPL
Amy Alvarez
15 Apr 14 19:08:34
$RPRX Repros Completes Enrollm http://t.co/l3rsWcajoJ
BiotechSage
15 Apr 14 17:52:09
@Jabookie75 I like $BDSI $ADHD $BIOD $RPRX as low risks high reward at these levels
Sky Hunter
15 Apr 14 17:38:09
$RPRX Repros Completes Enrollment http://t.co/NKFTb7FM81
Lutz Braune
15 Apr 14 16:15:14
$RPRX Repros Completes Enrollment for Androxal Study http://t.co/3dAzbgGcDP
Lutz Braune
15 Apr 14 16:03:03
$RPRX Repros Completes Enrollment for Androxal Study http://t.co/HJCgNUgFHd
GavinGreenberg
15 Apr 14 15:34:36
$RPRX: Repros Completes Enrollment for Androxal Study http://t.co/kEAO9T3zLz
SNN Team
15 Apr 14 15:23:34
$RPRX - Repros Completes Enrollment for Androxal Study -> http://t.co/zsQSnYZcjC #stock #stocks #stockaction
Maddie Messina
15 Apr 14 11:40:08
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/2AjwZONAzA
Pelion Volos
15 Apr 14 11:01:32
added sm long $CNAT 6.11, $ARRY 3.4 + sold $RPRX 5/12.5 puts .8 ; also hedged 1/2 $ARIA short - sold 5/6 puts
Tyrell King
15 Apr 14 08:00:04
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/XxV6VPG6Y9
Larry Meath
15 Apr 14 07:15:24
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/f5PwowxQwj
Lekisha Longoria
15 Apr 14 06:56:35
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/XuxLFhNIOE
Mind Equity
15 Apr 14 04:37:45
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/umTkysKE3Z
Kohen Fisher
15 Apr 14 03:15:03
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/dhRGdfyeKy
The Amazing Seven
15 Apr 14 01:54:39
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/zcSV82YwBg
mHealth Reporter
14 Apr 14 21:58:11
RT @BV_Healthcare: $RPRX Repros Fully Enrolls First of Two Previously Announced Head to Head Studies .. http://t.co/1HipEHcMOa
BV Healthcare
14 Apr 14 21:53:53
$RPRX Repros Fully Enrolls First of Two Previously Announced Head to Head Studies .. http://t.co/1HipEHcMOa
Wes Martinez
14 Apr 14 19:51:49
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/o7trnQi7eP
PennyStockSage
14 Apr 14 17:12:43
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/2cDi5dQdxD
Octavio Van
14 Apr 14 13:52:07
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/HAt9tGSKaN
Angelena Mosesuo
14 Apr 14 12:33:33
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/hPaTzbPEeY
Kamren Dissana
14 Apr 14 09:15:34
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/R5CVjgFigv
Briefing.com
14 Apr 14 08:48:49
$RPRX: Repros Therapeutics fully enrolls first of two previously announced heat to head studies of Androxal vs the... http://t.co/IkoPDqDn4a
Lutz Braune
14 Apr 14 08:32:08
$RPRX Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of ... http://t.co/pnT0VSOQsY
OTPicks.com
14 Apr 14 08:16:00
http://t.co/rruxxSh4Kk $heff: $RPRX..Repros Fully Enrolls First of Two Previously Announ http://t.co/bZFLxgMJ2Q http://t.co/rruxxSh4Kk
Lutz Braune
14 Apr 14 08:09:39
$RPRX REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/3bok0evPGf
GavinGreenberg
14 Apr 14 08:07:40
$RPRX: 9:46 am Repros Therapeutics fully enrolls first of two previously anno... http://t.co/bp6lMwmAQN
LoveStockNews
14 Apr 14 07:57:07
$RPRX - 9:46 am Repros Therapeutics fully enrolls first of two previously anno... -> http://t.co/tQ7T6FGqKz #stock #stocks #stockaction
Stock Herald
14 Apr 14 07:47:05
$RPRX: REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events http://t.co/IoN6u0svCM
MarketNews
14 Apr 14 07:25:02
$RPRX - REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events -> http://t.co/1gIg2YTtYc #stock #stocks #stockaction
				
				
By  +Follow September 17, 2013 8:01AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.